

# EuroSIDA Newsletter

October 2017



## ANNOUNCEMENTS

### Dear EuroSIDA Study Investigators,

It has been a while since the last newsletter and we are happy to once again send you updates on the EuroSIDA study. Let us repeat, that your continued excellent work and important contributions to the EuroSIDA study are instrumental to our high level of scientific research and your efforts are very highly valued.

## Study updates

### Dataset 45

Dataset 45 was released on 5th October 2017. We apologise profoundly for the delay and for the inconvenience this caused to many of you.

The deadline for completing dataset 45 is **4th December 2017**. If you experience any problems with the dataset or have any suggestions, please always feel free to contact the EuroSIDA coordinating centre. Please note the new **RESPOND Event form** to be completed in REDCap. Read more about it below.

### Plasma samples

From 1st October 2017, we now only request and reimburse:

**1 plasma sample per patient per year.**

We apologize for the change in routine and for any inconvenience this may cause. Plasma samples collected, stored and shipped already will of course be reimbursed in full.

If you wish to send more than the one sample per patient per year, we welcome the additional contribution, but prospectively we can only reimburse for one sample.

### LTFU

We have a continued focus on patients lost to follow-up (LTFU) in the EuroSIDA study. A low LTFU is crucial in order to secure high quality of the data we collect in the study. A low LTFU has been one of the hallmarks of EuroSIDA since the very beginning in 1994. We therefore ask you to please review your LTFU patients and check if there are any changes in the PIDs LTFU status. Please check 1. If the PID has returned to your clinic. 2. Whether some of the PIDs have died, and if yes, please complete a CoDe form for these patients. 3. Whether you have more FU data for the PIDs even if they are LTFU. If a patient has returned to your clinic, please let us know at the coordinating centre so we can upload the patient and patient data to the REDCap FU-forms.

### Ethics approvals

#### **Deadlines:**

##### **Dataset 45:**

**4 December 2017**

Please continue to complete HCV Treatment and Adverse Event forms, INSTI HSR forms, CoDe forms and RESPOND Event forms when relevant.

#### **EACS F2F:**

##### **EuroSIDA Investigator meeting:**

Friday 27 October 12.00-13.00 in  
Room IMR 3, Mezzanine level

##### **EuroSIDA SC meeting:**

Friday 27 October 07:00-08:00am in  
Room IMR 3, Mezzanine level

##### **ECDC/RESPOND Public Health Roundtable Meeting**

Wednesday 25 October 12.15-13.30  
in Room IMR4, Mezzanine level

#### **Upcoming TCs:**

##### **Hepatitis SIG:**

Monday 6 November 15:00 CET

##### **PrEP SIG:**

Tuesday 7 November 15:00 CET

##### **Outcomes SIG:**

Friday 24 November 12:00 CET

### **New Steering Committee**

During 2017 EuroSIDA Steering Committee elections were held. You can find the new EuroSIDA Steering Committee [HERE](#).

A HUGE thank you to the retiring Steering Committee, for the invaluable

Please remember that EC Approval is the responsibility of the sites. This includes initial applications, amendments, coverage of biologic samples collection and continuation of approvals. However, we aim to assist in any way we can, and also reimburse you if there are fees for your approval process. Please also remember, that CHIP needs a copy!

## EACS 2017

We would like to invite all EuroSIDA investigators to join us at the

**EuroSIDA F2F investigator meeting  
at the 16th European AIDS Conference in Milan  
Friday 27 October 12.00-13.00  
In Room IMR 3, Mezzanine level**

Please confirm if you are attending, if you have not already done so, to [eurosida.rigshospitalet@regionh.dk](mailto:eurosida.rigshospitalet@regionh.dk) (lunch will be served). We hope to see many of you at the meeting, for study updates and F2F networking.

Additionally, at the upcoming EACS conference, ECDC, the European Health Programme INTEGRATE project on HIV linkage to care, and the **RESPOND Public Health SIG**, will convene HIV surveillance and clinical experts for an informal round table discussion on how collaboration across clinical and public health sectors could be extended and improved. The meeting will take place on **Wednesday 25 October 12:15-13:30** at the EACS conference venue.

### Presentations at EACS

EuroSIDA will be represented at EACS with 4 presentations, and we are pleased to announce that the EuroSIDA abstract "The hepatitis C cascade of care among HIV infected individuals in EuroSIDA" has been accepted as an oral presentation! You can find the presentations on our website after they have been presented at EACS.

#### Oral Presentation:

**The hepatitis C cascade of care among HIV infected individuals in EuroSIDA** presented by Sarah Amele  
27 October 2017: 10:15 AM in Room Barcelona. PS9/1

**Poster Presentations:** (26 & 27 October 2017 12:00-14:00 in the Exhibition Hall)

**Abacavir Usage Patterns and Hypersensitivity Reactions (HSR) in the EuroSIDA cohort** presented by Ashley Roen. PE9/25

**Occurrence of Hypersensitivity Reaction and Hepatotoxicity in Patients Receiving Integrase inhibitors: Results from the EuroSIDA study** presented by Leah Shepherd. PE12/7

contribution over the last 6 years and also a huge and warm welcome to the new Steering Committee!

### Updates on Staff

**Leah Shepherd** has defended her thesis and passed with no corrections. Unfortunately Leah is leaving us per 1 January 2018. A big thank you to Leah for her work great work with EuroSIDA and also big congratulations on her PhD and her new position.

**Kamilla Laut** will be handing in her PhD thesis on 31st October. We thank Kamilla as well for her excellent work with EuroSIDA during the past years.

### Contracts and reimbursement

In August 2017 a new EuroSIDA Sponsor-Site Agreement were sent to all Principle Investigators. Please review the contract and return it to us signed. We will have it countersigned and returned to you fully executed shortly after. Please feel free to ask us if you have any questions to the contract.

Reimbursement 2017, covering dataset 44, may be delayed as we need a copy of the contracts before we can reimburse all sites. We apologise for this and hope to get the process underway as soon as possible. Former EuroCoord partner sites will be reimbursed for their EuroSIDA activities in DS42-DS43 as well. We thank you all for your understanding and patience.

### REST

The RESPOND Electronic Submission Tool (REST) is a new CHIP-developed web based tool to check, survey and submit data for sites submitting data electronically in Access a data dump in EuroSIDA and RESPOND. REST generates a report of errors and the data are not submitted before you decide to do so in a final step. This means that REST may also serve as a tool for you to check for and correct

## Estimating the country-specific burden of late presentation to HIV care across Europe between 2010-2014

presented by Kamilla Laut on behalf of the Late Presentation Working Group in the COHERE and EuroSIDA studies. PE26/6

### RESPOND

EuroSIDA is a founding partner and major stakeholder in the new RESPOND consortium. We are contributing a significant amount of data and resources to RESPOND and we are an important member of the Executive Committee. RESPOND in turn is providing resources back to EuroSIDA to allow us to continue patient follow-up. Read more about RESPOND [HERE](#).

Following the transition to RESPOND, a few changes have been made in data collection and some data items have been added to the follow-up form to harmonize data with the RESPOND protocol. RESPOND has been successful in raising funding for central validation of clinical events. This means that we ask you to fill in a **new RESPOND Event form**, if a participant experiences one of the non-AIDS defining events requested. Please read the DS45 cover letter for more information.

Please feel free to contact us at the coordinating centre if you have any questions about RESPOND or EuroSIDA's role in RESPOND.



### Scientific interest groups

It is a natural step for many of the research questions developed within the scientific interest groups to be addressed within the larger RESPOND network, and the SIGs will gradually merge with RESPOND SIGs, drawing on the expertise from the EuroSIDA team as well as the RESPOND team.

The **'Patient Management'** and **'Comorbidities & pharmacovigilance'** SIGs have been morphed into the **'Outcomes with ARVs'** SIG.

The **Public Health** SIG and the **Hepatitis** SIG continue their important work under the auspices of RESPOND.

Additionally, the **PrEP** SIG and the **Tuberculosis** SIG have identified very promising research proposals that we hope will take form in the near future.

All SIGs have shown great progress, identifying innovative and strong research proposals. Please remember that all are welcome to carry forward any research idea. Proposals can be submitted [HERE](#). We look forward to continue this essential work with you in

errors before submitting data.

Please read the REST User Guide on our website for further information.

If you need REST access, please contact the Coordinating center.

### EuroSIDA study documents

Please remember that you can find relevant study documents [HERE](#).

### Change in staff and REDCap login

Please remember to update the EuroSIDA coordinating centre if there are changes to staff. This allows information, newsletters etc. to be sent to the right person and also allows us to keep the study group updated and thus award co-authorships to the right people. Furthermore, if staff no longer works at your site, we need to remove their REDCap access.

### European HIV-Hepatitis Testing Week 2017

It's not too late to sign-up for European Testing Week (ETW). We recommend EuroSIDA investigators to sign-up and participate. ETW takes place from 17-24 November. Policy makers, healthcare professionals and civil society organisations unite for this one week to help people become aware of their HIV and/hepatitis status. Sign-up [HERE](#).



### Contact

Please always feel free to contact the EuroSIDA coordinating centre at [eurosidea.rigshospitalet@regionh.dk](mailto:eurosidea.rigshospitalet@regionh.dk). No question is too small or too big, we are happy to assist in all matters!

the future!

## PUBLICATIONS

Total number of publications in 2017: 10

Publications since last newsletter May 2017: 3

**Antiretrovirals, fractures and osteonecrosis in a large international HIV cohort.** Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink HJ, Uzdaviniene V, Tomazic J, Gargalianos-Kakolyris P, Schmid P, Orkin C, Pedersen C, Leen C, Pradier C, Mulcahy F, Ridolfo AL, Staub T, Maltez F, Weber R, Flamholz L, Kyselyova G, Lungren JD, Mocroft A; for EuroSIDA. Clin Infect Dis. 2017;64(10):1413-1421.

**Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. HIV Controllers Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCOORD.** PLoS One. 2017;12(4):e0173893.

**Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.** Chêne G, Phillips A, Costagliola D, Sterne JA, Furrer H, Del Amo J, Mocroft A, d'Arminio Monforte A, Dabis F, Miro JM, Barger D, Termote M, Schwimmer C, Salbøl Brandt R, Friis-Møller N, Raben D, Haerry D, Egger M, Weller I, De Wit S. Int J Epidemiol. 2017;1;46(3):797-797n.

## IN PRESS

**Predictors of eGFR Progression, Stabilisation or Improvement After Chronic Renal Impairment in HIV-positive individuals.** L Ryom, A Mocroft, O Kirk, M Ross, C Smith, O Moranne, P Morlat, CA FUX; C Sabin, A Phillips, M Law, JD Lundgren. On behalf of the D:A:D Study group. AIDS. 2017 Mar 28. [Epub ahead of print].

**Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens.** A Cozzi-Lepri, R Zangerle, L Machala, K Zilmer, M Ristola, C Pradier, O Kirk, J Grarup, Helen Sambatakou, Gerd Fätkenheuer, Israel Yust, Patrick Schmid, Magnus Gottfredsson, Irina Khromova, David Jilich, Robert Flisiak, Jelena Smidt, Baiba Rozentale, Roxana Radoi, Marcelo H Losso, JD Lundgren, A Mocroft on behalf of EuroSIDA. HIV Med. 2017 Oct 6. [Epub ahead of print].

**Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study.** A.M. W. Efsen, A. Schultze, R.F. Miller, A. Panteleev, A. Skrahin, D.N. Podlekareva, J.M. Miro, E. Girardi, H. Furrer, M.H. Losso, J. Toibaro,



J. A. Caylà, A. Mocroft, J.D. Lundgren, F.A. Post, O. Kirk, for the TB:HIV study in EuroCoord.

Accepted for publication in J of Infection, October 2017

**The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people.**

Shepherd L, Borges ÁH, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M, Viard JP, Bogner JR, Gargalianos-Kakolyris P, Mussini C, Mansinho K, Yust I, Paduta D, Jilich D, Smiatacz T, Radoi R, Tomazic J, Plomgaard P, Frikke-Schmidt R, Lundgren J, Mocroft A for EuroSIDA in EuroCOORD.

HIV Med. 2017. [Epub ahead of print]

**The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.**

A Schultze, R Paredes, C Sabin, AN Phillips, D Pillay, N Mackie, A Castagna, D Chadwick, K Falconer, AM Geretti, FA Post, T Hill, O Kirk, A Pozniak, M Nelson, A Tostevin, D Dunn, J Lundgren, A Cozzi-Lepri.

Antivir Ther. 2017 [Epub ahead of print]

**Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?**

A Mocroft, K Laut, P Reiss, J Gatell, V Ormaasen, M Cavassini, V Hadziosmanovic, K Mansinho, C Pradier, M Vasylyev, V Mitsura, L Vandekerckhove, L Ostergaard, A Clarke, O Degen, F Mulcahy, A Lazzarin, Z Sthoeger, L Flamholc, D Sedláček, I Mozer-Lisewska, JD Lundgren for the EuroSIDA study.

AIDS 2017

All EuroSIDA publications may be found [HERE](#)

Thank you for a continuous rewarding collaboration and for your invaluable contributions to EuroSIDA!